Shares of CareDx (NASDAQ:CDNA) climbed 7% Thursday amid news Natera (NTRA) was no longer pursuing infringement claims for two patents against CareDx’s current version of AlloSure Kidney.

AlloSure Heart is Now Validated and Commercially Available for Pediatric Heart Transplant Patients Under 15 AlloSure Kidney is Now Validated and Commercially Available for Simultaneous Pancreas ...

It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients ...

5 As with other organ transplants, the organs are at risk of rejection. AlloSure Kidney has been clinically validated to identify rejection and graft injury in SPK patients. 6-7 AlloSure Kidney ...

high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and ...